New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cytarabine 100 mg/ml - solution for injection - 100 mg/ml - active: cytarabine 100 mg/ml excipient: water for injection - cytarabine is indicated primarily for: · induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as · acute lymphocytic leukaemia · chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine. remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity. cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cytarabine 20 mg/ml - solution for injection - 20 mg/ml - active: cytarabine 20 mg/ml excipient: sodium chloride water for injection - cytarabine is indicated primarily for: · induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as · acute lymphocytic leukaemia · chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine. remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity. cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - omeprazole magnesium 10.3mg equivalent to 10 mg omeprazole;   - enteric coated tablet - 10 mg - active: omeprazole magnesium 10.3mg equivalent to 10 mg omeprazole   excipient: crospovidone ferrous oxide glyceryl monostearate hypromellose methacrylic acid-ethyl acrylate copolymer (1:1) hydroxypropylcellulose iron oxide yellow macrogol 6000 magnesium stearate microcrystalline cellulose polysorbate 80 purified talc sodium hydroxide sodium stearyl fumarate sugar spheres synthetic paraffin titanium dioxide triethyl citrate

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - omeprazole magnesium 20.6mg equivalent to 20 mg omeprazole;   - enteric coated tablet - 20 mg - active: omeprazole magnesium 20.6mg equivalent to 20 mg omeprazole   excipient: crospovidone ferrous oxide glyceryl monostearate hard paraffin hyprolose hypromellose methacrylic acid-ethyl acrylate copolymer (1:1) macrogol 6000 magnesium stearate microcrystalline cellulose polysorbate 80 purified talc sodium hydroxide sodium stearyl fumarate sugar spheres titanium dioxide triethyl citrate - the short-term relief of reflux-like symptoms in patients aged 18 years and over.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - capecitabine 150mg;   - film coated tablet - 150 mg - active: capecitabine 150mg   excipient: croscarmellose sodium hypromellose lactose magnesium stearate microcrystalline cellulose opadry pink 03a14309 - xeloda is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - capecitabine 500mg;   - film coated tablet - 500 mg - active: capecitabine 500mg   excipient: croscarmellose sodium hypromellose lactose magnesium stearate microcrystalline cellulose opadry pink 03a14380 - xeloda is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sinochem international australia pty. ltd. - diflufenican; bromoxynil present as the octanoate; n-methyl-2-pyrrolidone; liquid hydrocarbon - emulsifiable concentrate - diflufenican anilide/aniline-nicotinanilide active 25.0 g/l; bromoxynil present as the octanoate nitrile active 250.0 g/l; n-methyl-2-pyrrolidone solvent other 175.0 g/l; liquid hydrocarbon solvent other 397.0 g/l - herbicide

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose   iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose purified talc purified water   titanium dioxide - capecitabine winthrop is indicated for the treatment of patients with locally advanced or / metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine winthrop in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - capecitabine 500mg - film coated tablet - 500 mg - active: capecitabine 500mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose   iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose purified talc purified water   titanium dioxide - capecitabine winthrop is indicated for the treatment of patients with locally advanced or / metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine winthrop in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: croscarmellose sodium hypromellose opadry pink 03a540004 lactose magnesium stearate microcrystalline cellulose - capercit tablets are indicated for the adjuvant treatment of patients with dukes stage c and higher-risk stage b colon cancer, either as monotherapy or in combination with oxaloplatin